Source comparison
Dose-Tapering Protocols vs Block Cycling
Traditional block cycling. 4 weeks on at therapeutic dose, then 4 weeks completely off. Works well for compounds where the goal is resetting negative feedback (insulin, thyroid hormones) or clearing accumulated metabolites (anabolic androgens). It doesn't addr
This comparison does not assign a generated winner or score.
- Traditional block cycling. 4 weeks on at therapeutic dose, then 4 weeks completely off. Works well for compounds where the goal is resetting negative feedback (insulin, thyroid hormones) or clearing accumulated metabolites (anabolic androgens). It doesn't address use-dependent receptor desensitization effectively. An alternative approach supported by melanocortin pharmacology literature: dose tapering combined with extended inter-dose intervals.
- The protocol structure: begin with standard dose (1.5–2.0mg subcutaneously) administered every 96 hours for three doses. Then reduce to 1.0mg every 96 hours for two doses. Then 0.75mg every 120 hours for two doses. Then discontinue for 10–14 days. The taper reduces cumulative receptor internalization load while maintaining some degree of pathway activation, and the extended intervals allow progressive receptor recovery rather than forcing full depletion followed by full resaturation. Phase I pharmacokinetic studies from Palatin Technologies (the developer of bremelanotide) used similar tapered-discontinuation protocols in their safety trials and noted more stable subjective response profiles compared to abrupt-start/abrupt-stop cohorts.
- This isn't a universal protocol. It's one framework that aligns with melanocortin receptor trafficking dynamics better than standard block cycling. Researchers working with Real Peptides compounds have access to precise dosing increments that allow this kind of granular titration, which isn't possible with pre-filled pharmaceutical delivery systems locked at fixed doses. The ability to prepare exact microgram doses from lyophilized powder enables protocol flexibility that matches receptor biology rather than forcing biology to match convenient dosing schedules.